tbuckley/cabot-search huggingface dataset:
RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL).
Authors: E. A. Hawkes, I. Chau, K. Thomas, J. R. Oates, J. Webb, C. Costello, P. W. Johnson, D. Cunningham
Journal: Journal of Clinical Oncology (2010)

TPS304 Background: RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard of care for pts with DLBCL yet cure rates remain only 50-60% (Feugier et al JCO 2005). Vascular endothelial growth factor (VEGF) is a pro-angiogenic factor in pathologic angiogenesis and has also been implicated in lymphomagenesis (Potti, Anticancer Res 2002). Elevated VEGF gene expression correlates with poor prognosis in DLBCL. High serum VEGF has been strongly associated with poor clinical outcomes independent of other predictive factors (Kuramoto Br J Haematol 2002). B is a humanized monoclonal antibody that binds VEGF with activity in solid tumors. The combination of RCHOP + B is feasible in NHL. One phase II trial treated 13 pts with RCHOPB 21, with an observed response rate (RR) of 85% and grade 2 cardiotoxicity (CT) in 1/13 pts (Ganjoo JCO 2005). There are limited data reporting cardiotoxic effects of B particularly in combination with other cardiotoxic agents such as anthracyclines. In solid tumor trials CT has ranged from 2% to 35% (Miller et al JCO 2005, D'Adamo et al JCO 2005). While expected to be low, characterization of this potentially serious toxicity in a larger cohort is needed. Methods: Study Design: Phase II multicentre single arm trial. n=28 (7 recruited). Simon 1 stage design, 80% power and 1-sided alpha 0.05 to rule out CT and B-related toxicity rate of 30% (p0=70%) assuming expected CT rate=10% (p1=90%). Study opened May 2008. Treatment: Standard dose RCHOP 21 + B (15 mg/kg) × 6-8 Cycles 3 weekly followed by B monotherapy × 6 3 weekly. Primary Endpoint: CT and B-specific toxicity (CTCAEv3.0). Defined as: Grade 2-4 LV dysfunction or decreased LVEF > 15%, grade 3/4 arrhythmia, myocardial ischaemia/infarction related to B & B related toxicities such as hypertension, proteinuria, bleeding, thrombosis, GI perforation. Occurring within 30 days post-treatment. Main Eligibility: Previously untreated DLBCL Stage II-IV. LVEF>50% on MUGA or Echocardiogram. No DLBCL involvement of GI tract, proteinuria, recent surgery, active wound, bleeding diathesis or coagulopathy, indolent lymphoma. Follow-up: Restaging and MUGA/Echo every 2 cycles, post-treatment then at 1 yr. Clinical review for 5 yrs. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche Roche
AMSSM Position Statement on Cardiovascular Preparticipation Screening in Athletes: Current evidence, knowledge gaps, recommendations and future directions
Authors: Jonathan A Drezner, Francis G O'Connor, Kimberly G Harmon, Karl B Fields, Chad A Asplund, Irfan M Asif, David E Price, Robert J Dimeff, David T Bernhardt, William O Roberts
Journal: British Journal of Sports Medicine (2016)

Cardiovascular screening in young athletes is widely recommended and routinely performed prior to participation in competitive sports. While there is general agreement that early detection of cardiac conditions at risk for sudden cardiac arrest and death (SCA/D) is an important objective, the optimal strategy for cardiovascular screening in athletes remains an issue of considerable debate. At the centre of the controversy is the addition of a resting ECG to the standard preparticipation evaluation using history and physical examination. The American Medical Society for Sports Medicine (AMSSM) formed a task force to address the current evidence and knowledge gaps regarding preparticipation cardiovascular screening in athletes from the perspective of a primary care sports medicine physician. The absence of definitive outcome-based evidence at this time precludes AMSSM from endorsing any single or universal cardiovascular screening strategy for all athletes, including legislative mandates. This statement presents a new paradigm to assist the individual physician in assessing the most appropriate cardiovascular screening strategy unique to their athlete population, community needs and resources. The decision to implement a cardiovascular screening programme, with or without the addition of ECG, necessitates careful consideration of the risk of SCA/D in the targeted population and the availability of cardiology resources and infrastructure. Importantly, it is the individual physician's assessment in the context of an emerging evidence base that the chosen model for early detection of cardiac disorders in the specific population provides greater benefit than harm. AMSSM is committed to advancing evidenced-based research and educational initiatives that will validate and promote the most efficacious strategies to foster safe sport participation and reduce SCA/D in athletes.
Interferon-Free Treatment of Chronic Hepatitis C with Direct-Acting Antiviral Agents: Age is No Longer an Unfavorable Prognostic Factor
Authors: A. Pariente, A.-J. Rémy, J.-P. Arpurt, C. Renou, F. Heluwaert, H. Lison, R. Arotcarena, I. Rosa-Hézode, A. Pauwels, F. Bourhis, G. Macaigne, X. Causse, G. Barjonet, S. de Montigny-Lenhardt, H. Salloum, C. Pilette, S. Hommel, M. Schnee, E. Geagea, E. Maringe, Y. Le Bricquir, H. Labadie, J. Henrion, H. Hagège, B. Lesgourgues
Journal: Journal of Hepatology (2016)
Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads to Earlier Engraftment and Higher Donor Chimerism Than Busulfan/Cyclophosphamide, and Enables the Use of Mismatched and Unrelated Donors for Transplantation in Haemoglobinopathies
Authors: Farah O'Boyle, Natalie Killeen, Mikel Valganon, Subarna Chakravorty, Leena Karnik, Helen New, Letizia Foroni, Richard Szydlo, Irene Roberts, Josu de la Fuente
Journal: Blood (2012)
Observational study of patients with non-small cell lung cancer (NSCLC) treated by erlotinib: Clinical practices and main outcomes in France (OBSTAR).
Authors: A. Vergnenegre, I. Monnet, C. Chouaid, J. Hureaux, J. Mazieres, G. Quere, J. Lombard, I. Cumin, S. Abdiche, C. Decroisette
Journal: Journal of Clinical Oncology (2010)

e12031 Background: Few data are available about the use of erlotinib in the real life in France for patients with non small cell lung cancer (NSCLC). The objective of this epidemiological study was to describe the use of erlotinib out of clinical trials. Methods: An epidemiological multicenter observational study was conducted in 35 french centers. The study was retrospective (starting from September 2006 to September 2008), with a follow-up period of one year. The main objective was to describe the progression free survival (PFS), according to the indication and to patients' subgroups. Results: 497 patients have been included in the study, 30 (6%) in first-line treatment, 177 (36%) in second line, 239 (48%) in third line, 43 (9%) in other and 8 (2%) in maintenance indication. The histological types were as follows: 304 (62%) adenocarcinoma, 99 (20%) squamous cell carcinoma, 60 (12%) large cell carcinoma and 30 (6%) others. Erlotinib was given to 311 (63%) male and 186 (37%) female. The indications were as follows: 7 (2%) post surgical stage II-III NSCLC, 31 (7%) locally advanced NSCLC, 417 (91%) advanced NSCLC. Conclusions: Erlotinib was approved in Europe as a second line treatment for patients who had progressed after at least one regimen of chemotherapy in September 2005. This study showed that erlotinib is used in different indications but preferentially as a second line treatment in male patients with adenocarcinoma. Updated descriptive data, safety profile, outcome including PFS and clinical predictive factors will be reported at the meeting. Supported by an educational grant from Roche company. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Roche Amgen, Lilly, Roche Amgen, Lilly, Roche
Combination of the Hepatitis B/D Entry Inhibitor Myrcludex B and Tenofovir: Assessment of the Effect on Plasma Bile Acid Profiles and Tenofovir Pharmacokinetics
Authors: A. Blank, A. Eidam, M. Haag, N. Hohmann, J. Burhenne, L. Witt, M. Meyer, M. Schwab, G. Mikus, A. Alexandrov, S. Urban, W.E. Haefeli
Journal: Journal of Hepatology (2016)
Fueling Cellular Division during Liver Regeneration: CDK1 Regulates Energy Metabolism by Directing the Flux of Pyruvate
Authors: M. Caldez, N. Van Hul, X.Q. Teo, T. Fuhrer, J.J. Fan, P.Y. Tan, W. Stunkel, H. Yu, M. Bjorklund, U. Sauer, P. Lee, P. Kaldis
Journal: Journal of Hepatology (2016)
Multicentric Prospective Study of Validation of Angiogenesis Polymorphisms in HCC Patients Treated with Sorafenib. Innovate Study
Authors: A.C. Gardini, L. Faloppi, B. Daniele, G.F. Foschi, S. Cascinu, G. Marisi, G. Masi, L. Chessa, F. Negri, E. Scarpi, D. Santini, J. Corbelli, N. Silvestris, E. Tamburini, V. Zagonel, M. Scartozzi
Journal: Journal of Hepatology (2016)
Spontaneous Bacteremia in Patients with Cirrhosis: Characteristics and Outcomes
Authors: S. Marciano, C. Bermudez, N. Sobenko, L. Haddad, F.G. Bert, L. Barcán, A. Smud, M.L. Posadas-Martinez, D. Giunta, A. Gadano
Journal: Journal of Hepatology (2016)
El Niño’s Impact on Children
Authors: M.J. Friedrich
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study
Authors: K. Deterding, C. Spinner, E. Schott, T. Welzel, G. Gerken, H. Klinker, U. Spengler, J. Wiegand, J. Schulze zur Wiesch, A. Pathil, M. Cornberg, A. Umgelter, C. Zöllner, S. Zeuzem, H. von der Leyen, D. von Witzendorff, M.P. Manns, H. Wedemeyer
Journal: Journal of Hepatology (2016)
The Validation of a Newly Updated Child-Turcotte-Pugh Core Using Insulin Growth Factor-1 for Predicting Survival of Patients with Hepatocellular Carcinoma in Chronic Hepatitis B Endemic Area
Authors: D.H. Lee, J.-H. Lee, Y. Cho, Y.Y. Cho, E.J. Cho, S.J. Yu, Y.J. Kim, J.-H. Yoon
Journal: Journal of Hepatology (2016)
Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance
Authors: A. Gastaldelli, M. Gaggini, G. Daniele, N. Musi, C. Triplitt, D. Ciociaro, P. Fox, D. Tripathy, R. DeFronzo, P. Iozzo
Journal: Journal of Hepatology (2016)
Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.
Authors: A. P. Palumbo, M. Delforge, J. Catalano, R. Hajek, M. Kropff, M. T. Petrucci, Z. Yu, J. M. Mei, M. A. Dimopoulos
Journal: Journal of Clinical Oncology (2011)

8007 Background: MM pts have an 8-10 fold higher risk of developing acute myeloid leukemia (AML) than the general population. MM-015 compared MPR-R vs fixed-duration MP or MPR in transplant-ineligible pts ≥65 yrs. This analysis evaluated SPM incidence rates (IRs) and standardized incidence ratios (SIR). Methods: IRs were calculated for AML and solid tumor (ST) malignancies. Expected IRs used to calculate SIR were derived from 23,838 MM pts identified in the Surveillance, Epidemiology, and End Results (SEER) Cancer Registries between 1973-2000 (Dores 2006). Results: As of May 2010 cut-off, total cases of SPM were 4/150 in MPR-R (IR=1.40), 6/152 in MPR (IR=2.05) and 2/153 in MP (IR=0.67), including 2 myelodysplastic syndromes cases in MPR-R and 2 AML cases in each of MPR-R and MPR. 11 pts with complex cytogenetics were randomized to MPR-R/MPR and none randomized to MP. Of these, 3 developed AML; 2 MDS. ST were of heterogeneous tumor types. No B-cell malignancies were reported. Median progression-free survival (PFS) of MPR-R vs MP was 31 vs 13 mos (P < .001; median follow-up: 25 months), with a reduced risk of progression of 60% (hazard ratio [HR] = 0.395). When SPM were added as additional events for PFS, results remained unchanged (HR = 0.408; P <.001). Conclusions: An imbalance of AML incidence was observed in MPR/MPR-R vs MP, but incidence was low (0.7% vs 0%) and associated with complex baseline cytogenetics. ST IRs were low and similar for all arms. At present, the SPM risk is similar to that reported in other studies. Longer follow-up is needed to definitively assess the risk of SPM in NDMM pts receiving lenalidomide and alkylating agents. Evaluation will continue with updated data at the meeting. Variable MPR-R (n = 150) MPR (n = 152) MP (n = 153) AML PYa 288.47 294.54 301.04 Cases, obs/exp 2/0.42 2/0.43 0/0.44 IRb 0.69 0.68 0 SIR (95% CI) 4.76 (0.80-15.73) 4.65 (0.78-15.37) N/A Solid tumors PYa 286.74 292.40 299.93 Cases, obs/exp 1/4.02 3/4.1 2/4.2 IRb 0.34 1.03 0.67 SIR (95% CI) 0.24 (0.01-1.23) 0.72 (0.18-1.99) 0.48 (0.08-1.57) Abbreviation: CI, confidence interval; PY, person-years. a Double-blind, open-label, long-term follow-up.b Per 100 PY.
The Evolution of Portal Pressure after Viral Suppression with Interferon-Free Therapies and its Correlation with the Change in Liver Stiffness
Authors: M. Mandorfer, K. Kozbial, P. Schwabl, C. Freissmuth, R. Schwarzer, R. Stern, D. Chromy, T. Reiberger, A.F. Staettermayer, W. Sieghart, S. Beinhardt, M. Trauner, H. Hofer, A. Ferlitsch, P. Ferenci, M. Peck-Radosavljevic
Journal: Journal of Hepatology (2016)
Predictors of nonadherence to oral adjuvant hormonal therapy for breast cancer.
Authors: S. C. Lee, T. Chiou
Journal: Journal of Clinical Oncology (2010)

e11095 Background: Nonadherence to oral hormonal therapy has been well-documented. Fail to adhere to the adjuvant may lead to increase recurrence. Nonadherent behavior to oral medication was not limited to taking less but also alternating dose or schedule. The purpose was to investigate the indication of nonadherence behaviors to oral adjuvant hormonal therapy and the predictors of nonadherence in a sample of 125 women with breast cancer, receiving oral adjuvant hormonal therapy from 4 sites across Taiwan. Methods: Nonadherence was measured both by self-report and prescription refill data printed on the drug bottles. The self-reported measure was a 7-item 5-points scale, for level of adhering to the frequency, dosage and schedule for the past month. The non-adherence was also defined as fewer than 80% of pills according to the prescription and refill information. Predicators being investigated included the menopausal related symptom as measured by Breast Cancer Prevention trial Symptom Checklist, decisional conflict as measured by Decisional Conflict Scale, physician communication and socio-demographic-clinical data. Multivariate analysis was used to determine the predictors. Results: A majority of were in mid-age, married and receiving tamoxifen (68.8%). Results indicated 70%-82.4% women reported to have cognitive, sleep and fatigue issues; 60% of them being distressed with sexual issues. Hot flash and night sweat were only accounted for 48% and 37.6%. But 10% of the women reported to have more than 5 times of hot flash and night sweat, and woke up 3-4 times per night. 28% reported stopped taking the pills several times, about 10% alternated the dose, schedule and frequency. 27.8% were nonadherent according to refill data. The multiple regression analysis indicated that the nonadherent were more likely to be those who had been under the treatment longer, uncertainty about the adjuvant hormonal therapy and experienced bladder control issues. Conclusions: The findings indicated the nonadherent behaviors might go beyond taking less. An integrated intervention to assist these women to adhere the oral adjuvant is important. No significant financial relationships to disclose.
The gastric acid pocket is attenuated in<i>H. pylori</i>infected subjects
Authors: David R Mitchell, Mohammad H Derakhshan, Angela A Wirz, Clare Orange, Stuart A Ballantyne, James J Going, Kenneth E L McColl
Journal: Gut (2016)

<h3>Objective</h3> Gastric acid secretory capacity in different anatomical regions, including the postprandial acid pocket, was assessed in <i>Helicobacter pylori</i> positive and negative volunteers in a Western population. <h3>Design</h3> We studied 31 <i>H. pylori</i> positive and 28 <i>H. pylori</i> negative volunteers, matched for age, gender and body mass index. Jumbo biopsies were taken at 11 predetermined locations from the gastro-oesophageal junction and stomach. Combined high-resolution pH metry (12 sensors) and manometry (36 sensors) was performed for 20 min fasted and 90 min postprandially. The squamocolumnar junction was marked with radio-opaque clips and visualised radiologically. Biopsies were scored for inflammation and density of parietal, chief and G cells immunohistochemically. <h3>Results</h3> Under fasting conditions, the <i>H. pylori</i> positives had less intragastric acidity compared with negatives at all sensors &gt;1.1 cm distal to the peak lower oesophageal sphincter (LES) pressure (p&lt;0.01). Postprandially, intragastric acidity was less in <i>H. pylori</i> positives at sensors 2.2, 3.3 and 4.4 cm distal to the peak LES pressure (p&lt;0.05), but there were no significant differences in more distal sensors. The postprandial acid pocket was thus attenuated in <i>H. pylori</i> positives. The <i>H. pylori</i> positives had a lower density of parietal and chief cells compared with <i>H. pylori</i> negatives in 10 of the 11 gastric locations (p&lt;0.05). 17/31 of the <i>H. pylori</i> positives were CagA-seropositive and showed a more marked reduction in intragastric acidity and increased mucosal inflammation. <h3>Conclusions</h3> In population volunteers, <i>H. pylori</i> positives have reduced intragastric acidity which most markedly affects the postprandial acid pocket.
Decreasing the Risk of HCC in Caucasian Chronic Hepatitis B Patients under NUCS: Results of the Spanish Chronic Hepatitis B Registry (Ciberhep)
Authors: D. Tabernero, M. Riveiro-Barciela, J.L. Calleja, J.M. Sánchez-Tapias, M.L. Manzano, V. Moreira, J. Crespo, B. Piqueras, J.M. Pascasio, J.C. Erdozain, C.M. Fernandez, A. Aguirre, E. Suárez, F. Gea, M. Rivero, D. Acero, M. Fernandez-Bermejo, D. Moreno, P. Sánchez-Pobre, B.D. Cuenca, J.J. Moreno, R. Esteban, M. Buti
Journal: Journal of Hepatology (2016)
Medicare’s Bundled Payment Program for Joint Replacement
Authors: Elliott S. Fisher
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunosuppressive Therapy in Children with Refractory Anemia: Results of Japanese Childhood MDS Study Group Trial (MDS99).
Authors: Daisuke Hasegawa, Hiroshi Yagasaki, Yoshitoshi Ohtsuka, Masami Inoue, Akira Kikuchi, Akira Ohara, Masahiro Tsuchida, Seiji Kojima, Atsushi Manabe, Tatsutoshi Nakahata
Journal: Blood (2006)
How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software
Authors: Audrey Emmanuelle Dugué, Marina Pulido, Sylvie Chabaud, Lisa Belin, Jocelyn Gal
Journal: Clinical Cancer Research (2016)

We describe how to estimate progression-free survival while dealing with interval-censored data in the setting of clinical trials in oncology. Three procedures with SAS and R statistical software are described: one allowing for a nonparametric maximum likelihood estimation of the survival curve using the EM-ICM (Expectation and Maximization-Iterative Convex Minorant) algorithm as described by Wellner and Zhan in 1997; a sensitivity analysis procedure in which the progression time is assigned (i) at the midpoint, (ii) at the upper limit (reflecting the standard analysis when the progression time is assigned at the first radiologic exam showing progressive disease), or (iii) at the lower limit of the censoring interval; and finally, two multiple imputations are described considering a uniform or the nonparametric maximum likelihood estimation (NPMLE) distribution. Clin Cancer Res; 22(23); 5629-35. ©2016 AACR.
Steatometer: A New Ultrasound Imaging System for Non Invasive, Non-Ionizing Fatty Liver Measurement
Authors: F. Faita, N. Di Lascio, L. Cini, C. Avigo, A. Salvati, N. Martini, D. Chiappino, L. Ghiadoni, F. Bonino, M.R. Brunetto
Journal: Journal of Hepatology (2016)
Image Gallery: Complete remission of aggressive desmoid-type fibromatosis after low-dose methotrexate for 2 weeks in a child with psoriasis
Authors: S. Simonsen, A. Vera Casaño, E. Gómez Moyano, A. Sanz Trelles, C. Bravo Bravo, L. Martínez Pilar
Journal: British Journal of Dermatology (2016)

Funding sources: none. Conflicts of interest: none declared. Dear Editor, A 13‐year‐old girl with psoriasis presented with a 13 × 8‐cm subcutaneous mass in her shoulder (a, b). Strangely enough, she had had a radiologically similar mass in her leg, but it had suddenly vanished after starting treatment with low‐dose methotrexate for her psoriasis. A magnetic resonance imaging scan and biopsy of the current tumour were consistent with desmoid‐type fibromatosis (c, f). As surgery was rejected, we prescribed methotrexate 15 mg weekly. After 2 weeks, remission was complete and treatment suspended (d, e). Two years later there has been no recurrence. Desmoid‐type fibromatosis is a benign but infiltrative and recurrent tumour.1 Low‐dose methotrexate has been used successfully in some studies.2